Sourcing

How to Source Tranexamic Acid for Cosmetics: Pharma Grade vs Cosmetic Grade | Onerchem

How to Source Tranexamic Acid for Cosmetics: Pharma Grade vs Cosmetic Grade | Onerchem
Home / Knowledge / Sourcing Guides / Tranexamic Acid Sourcing
◆ B2B Sourcing Guide

How to Source Tranexamic Acid for Cosmetics: Pharma Grade vs Cosmetic Grade & What to Verify

Tranexamic Acid occupies an unusual position in the cosmetic ingredient market — it has decades of pharmaceutical history as a systemic antifibrinolytic drug, and a more recent but well-documented role as a topical brightening active. This dual-market background creates specific sourcing considerations that buyers need to understand before placing an order.

YR
Yang Ruosong
Content Strategist, Onerchem
April 2026
11 min read
Sourcing Guides

Pharmaceutical grade vs cosmetic grade — what actually differs

Tranexamic Acid (CAS 1197-18-8, trans-4-(aminomethyl)cyclohexane-1-carboxylic acid) is manufactured by a well-established chemical synthesis route and is commercially available in both pharmaceutical and cosmetic grades. Understanding the difference prevents two common mistakes: overpaying for pharmaceutical specifications that add no cosmetic value, and underpaying for inadequate documentation that creates regulatory exposure.

Pharmaceutical Grade
Ph. Eur. / USP monograph — drug GMP production
Purity
≥99.0% by HPLC per pharmacopeial monograph
GMP standard
Drug GMP (ICH Q7) — stricter than cosmetic GMP
Impurity limits
Pharmacopeial specific impurity limits for each named related substance
Documentation
Full pharmacopeial COA, drug master file eligible, batch records available
Cost
Higher — pharmaceutical production and testing overhead
Required for cosmetics?
No — but stronger quality signal; useful for highly regulated markets
Cosmetic Grade
HPLC ≥98% — cosmetic GMP production
Purity
≥98% HPLC purity — appropriate for cosmetic actives
GMP standard
Cosmetic GMP (ISO 22716) — appropriate for cosmetic ingredient supply
Impurity limits
General heavy metals, residual solvents, related substances — not pharmacopeial specific limits
Documentation
Batch COA, MSDS, TDS — suitable for cosmetic PIF requirements
Cost
Lower — cosmetic production and testing standard
Required for cosmetics?
Yes — this is the appropriate and sufficient grade for topical cosmetic use
The Right Choice for Most Buyers
For the vast majority of cosmetic applications, cosmetic grade TXA at ≥98% HPLC purity with full COA documentation is the correct specification. Pharmaceutical grade adds cost without adding formulation benefit — the difference in purity (98% vs 99%) is functionally irrelevant for topical cosmetic use where TXA acts as a surface-active agent affecting plasmin activity in the epidermis. The exception: if you are selling into a market where the product sits in a quasi-drug or cosmeceutical regulatory category that requires pharmaceutical-grade raw material documentation.

Why TXA works — the mechanism every buyer should understand

Understanding Tranexamic Acid's mechanism matters for sourcing because it determines what quality attributes are efficacy-critical versus what is supplier marketing language.

Tranexamic Acid is a synthetic lysine analogue. Its primary cosmetic mechanism is plasmin inhibition — it competitively blocks the lysine-binding sites on plasminogen, preventing its conversion to active plasmin. In the context of post-inflammatory hyperpigmentation (PIH):

  • ✓
    Plasmin inhibition — TXA blocks plasmin, which would otherwise stimulate arachidonic acid release from keratinocyte membranes. Less arachidonic acid means less prostaglandin E2 production.
  • ✓
    Prostaglandin cascade interruption — Reduced prostaglandin E2 means reduced activation of melanocyte-stimulating hormone (MSH). The signal that tells melanocytes to upregulate tyrosinase expression is intercepted before it reaches the tyrosinase level.
  • ✓
    Upstream intervention — This makes TXA uniquely valuable in PIH formulas: it works at Stage 1 of the melanin cascade, before tyrosinase inhibitors (Alpha-Arbutin, Kojic Acid) even become relevant. No single tyrosinase inhibitor can replicate this upstream effect.

TXA's efficacy comes from its molecular identity — it is a lysine analogue that fits specific binding sites. The purity and identity verification on the COA directly determine whether you have the compound capable of this mechanism. This is why COA quality matters, not marketing language about "clinical-grade" or "premium quality."

Use concentration — what the data supports

  • ✓
    2–3% — Primary evidence-supported concentration range for topical TXA in PIH treatment. Multiple published clinical studies on topical TXA use 2–3% and demonstrate significant reduction in melanin index versus control. This is the recommended concentration range for formulas making evidence-based brightening claims.
  • ✓
    3–5% — Upper cosmetic use range. Some formulas use up to 5% for intensive PIH treatment serums. Efficacy data above 3% is less differentiated — the dose-response relationship for topical TXA appears to plateau in published studies. Use above 3% is typically a marketing decision rather than an efficacy one.
  • ⚠
    Below 1% — Limited topical efficacy data at this range. TXA at below 1% may contribute to a formula as a supporting ingredient but should not carry primary brightening claims. If cost pressure pushes toward sub-1% inclusion, consider whether a different mechanism active (Alpha-Arbutin, Niacinamide) might better serve the formula goal at that concentration.
  • ⚠
    Above 5% — Approaching the practical solubility limit in water (approximately 8–10%). No significant additional efficacy data supports concentrations above 5% for topical use. Not recommended.

Formulation notes — TXA is one of the easiest actives to work with

One of Tranexamic Acid's most commercially valuable attributes is its formulation friendliness. Unlike Glutathione (oxygen-sensitive), Kojic Acid (strict pH requirement), or Glabridin (oil-soluble only), TXA imposes almost no special formulation constraints.

  • ✓
    Water phase addition, no heating required — TXA dissolves readily in water at ambient temperature at all cosmetic use concentrations (2–5%). Simply add to the water phase at room temperature. No pre-dissolution solvent, no heating, no special processing.
  • ✓
    Stable across pH 4.0–7.5 — TXA is chemically stable across the full cosmetic pH range. No acidic pH requirement (unlike L-Ascorbic Acid), no alkaline instability (unlike some peptides). Formula pH can be optimised for other actives without compromising TXA stability.
  • ✓
    Heat-stable to 80°C — TXA can be added to the heated water phase if preferred for process efficiency. No cool-down addition requirement. This simplifies manufacturing protocols for complex emulsions.
  • ✓
    No special packaging required — TXA does not require airless, opaque, or amber packaging for stability. Standard pump or airless dispensing is appropriate. This reduces packaging cost compared to oxygen-sensitive actives.
  • ✓
    Colourless and odourless — TXA is a white crystalline powder that produces a clear, colourless solution. No colour contribution to the finished formula — the formula appearance is fully controlled by other ingredients and pigments.

Compatibility — TXA works with everything

Co-ingredient Compatibility Notes
Niacinamide (4–5%) EXCELLENT Classic PIH combination. TXA inhibits signal upstream; Niacinamide inhibits melanosome transfer downstream. Complementary mechanisms, no interaction at pH 5.5–6.5.
Alpha-Arbutin (1–2%) EXCELLENT Three-node PIH coverage: TXA (signal), Alpha-Arbutin (tyrosinase), Niacinamide (transfer). Gold standard brightening combination — all water-soluble, compatible at pH 5.5–6.5.
3-O-Ethyl Ascorbic Acid COMPATIBLE Compatible across pH 5.0–6.5. 3-O-EAA adds antioxidant + direct brightening mechanism. Verify pH compatibility at your specific concentrations.
Peptides (Matrixyl, AH-8) COMPATIBLE No known interaction with cosmetic peptides at typical use levels. TXA + peptides is a natural combination for anti-aging brightening formulas.
Hyaluronic Acid COMPATIBLE No interaction. Both water-phase ingredients. Common in brightening serum architectures.
Retinol / Retinoids NOTE pH Compatible chemically. Retinoids prefer slightly higher pH (5.5–6.5) while TXA is stable across this range. Confirm stability of the retinoid in your specific formula pH.
AHAs (Glycolic, Lactic) NOTE pH TXA stable at AHA-required low pH (3.5–4.0). Confirm AHA concentration does not drive pH below TXA's effective range for the specific claim.
Standard preservatives COMPATIBLE Compatible with phenoxyethanol, sodium benzoate, potassium sorbate, ethylhexylglycerin systems at standard concentrations.

COA checklist for Tranexamic Acid

  • ✓
    CAS number: 1197-18-8 — Verify. Tranexamic Acid's CAS is unambiguous — no stereoisomer confusion risk like Alpha-Arbutin, no reduced/oxidised form distinction like Glutathione. The CAS confirmation is straightforward.
  • ✓
    HPLC purity ≥98% with chromatogram — For cosmetic grade. The chromatogram should show a clean dominant peak at the expected retention time with minor impurity peaks below 2% each. Pharmaceutical grade requires ≥99.0% per the relevant pharmacopeial monograph.
  • ✓
    Appearance: white crystalline powder — Any yellowing or off-white coloration is atypical and should be queried. TXA is a well-characterised compound with a consistent white appearance.
  • ✓
    Heavy metals: Pb, As, Cd, Hg quantitative — Required. Not "Pass" — actual measured values. TXA is a synthetic compound and heavy metal contamination risk is lower than for botanical extracts, but verification is still required for regulatory documentation.
  • ✓
    Residual solvents — TXA synthesis involves organic solvents. Request residual solvent testing confirming levels below applicable limits. For EU market, compliance with ICH Q3C or equivalent.
  • ✓
    pH of 1% solution — Typically pH 6.5–7.5 for TXA. A result significantly outside this range may indicate the wrong compound or contamination.
  • ✓
    Lot number and test date matching batch — Standard batch-specific COA requirements. See the COA Reading Guide for full checklist.
  • ⚠
    MSDS and TDS for EU PIF — Confirm your supplier can provide MSDS in GHS format and a Technical Data Sheet with cosmetic use guidance suitable for EU Product Information File compilation. This is required documentation for EU market launch and should be requested before ordering.
Product Page · Brightening Series
Tranexamic Acid (CAS 1197-18-8) — HPLC ≥98%, batch COA, MSDS, EU CosIng compliant
View Product
→

Regulatory status — cosmetic vs pharmaceutical claims

Tranexamic Acid's pharmaceutical history creates one specific regulatory caution for cosmetic use: claim positioning.

Claims Positioning
TXA is approved as a systemic pharmaceutical in many countries for antifibrinolytic indications (haemostasis, heavy menstrual bleeding). This pharmaceutical history means regulatory authorities in some markets may scrutinise TXA-containing cosmetics closely if claims approach therapeutic language.

Safe positioning: "brightening," "helps reduce the appearance of dark spots," "supports an even skin tone," "PIH-targeting formula."

Avoid: Any language referencing bleeding, coagulation, fibrinolysis, or therapeutic treatment of skin conditions. These cross into drug claim territory in most jurisdictions and will trigger regulatory review.

On the ingredient approval side, TXA is in a straightforward position for cosmetic use across all major markets: permitted in the EU (CosIng listed, no concentration restriction), China (IECIC), Japan, and the US. No pre-market approval is required in any of these markets for the cosmetic application. Supplier documentation should confirm CosIng compliance for EU market use.

Frequently asked questions

Pharmaceutical grade (Ph. Eur./USP) meets pharmacopeial monograph specifications at ≥99.0% purity under drug GMP conditions. Cosmetic grade meets cosmetic ingredient standards at ≥98% HPLC purity under cosmetic GMP. For topical cosmetic formulations, cosmetic grade is appropriate and sufficient. Pharmaceutical grade adds cost without adding formulation benefit at cosmetic use concentrations.
The evidence-supported concentration range for topical TXA in PIH treatment is 2–3%. Multiple clinical studies use 2–3% and demonstrate significant melanin index reduction. Below 1%, efficacy data is limited. Above 5%, the dose-response relationship plateaus and approaches the practical water solubility limit. For most formulas, 2–3% is the correct specification.
Yes. TXA is readily water-soluble — it dissolves at ambient temperature up to approximately 8–10% w/v, well above the 2–3% used in cosmetics. Add directly to the water phase at room temperature. No heating, no pre-dissolution solvent, and no special processing is required.
Yes — fully compatible with Niacinamide, all common cosmetic peptides, Alpha-Arbutin, Vitamin C derivatives, and standard preservative systems. TXA + Niacinamide + Alpha-Arbutin is a well-documented high-performance PIH formula covering three independent brightening mechanisms with no compatibility issues at pH 5.5–6.5.
Permitted for cosmetic use in the EU (CosIng listed), China (IECIC), Japan, and the US. No concentration restriction in major markets. Note that TXA has pharmaceutical history as an antifibrinolytic drug — ensure marketing claims are positioned as cosmetic (brightening, skin tone), not therapeutic. Drug-adjacent language will trigger regulatory scrutiny in most markets.
YR
Yang Ruosong
Content Strategist · Onerchem
LinkedIn →

Leave a Reply

Your email address will not be published. Required fields are marked *